The deleterious effects of hyperuricemia (HUA) on cardiovascular disease (CVD) were well established. Aspirin is the most commonly prescribed antiplatelet agent for primary or secondary prophylaxis of CVD. Only a few short-term studies in the elderly suggested low-dose aspirin, e.g., 75-100 mg/day, increases serum urate by reducing urinary uric acid excretion. However, monitoring of renal function is currently not recommended. Little is known about the long-term effect of low dose aspirin on uric acid. The principal aim of this prospective cohort study therefore is to evaluate the renal effects of long-term aspirin (100 mg/d) administration in Chinese patients with coronary artery disease or other CVDs.
Study Type
OBSERVATIONAL
Enrollment
2,000
Aspirin 100mg will be prescribed for antiplatelet therapy at the physician's discretion
Clopidogrel will be prescribed for antiplatelet therapy in case of aspirin intolerance at the physician's discretion
Shanghai Zhongshan Hospital
Shanghai, Shanghai Municipality, China
RECRUITINGHUA ( serum uric acid level, μmol/L)
Two different days of fasting uric acid \>420 μmol/L and women \>360 μmol/L under normal purine diet.
Time frame: 24 months after enrollment
Gout attacks (ACR/EULAR classification criteria 2015)
Gout attacks are confirmed according to ACR/EULAR classification criteria 2015
Time frame: 24 months after enrollment
Initiation of UA-lowering agents
Starting febuxostat, allopurinol,or benzbromarone therapy at physicians' descretion
Time frame: 24 months after enrollment
Renal impairment (serum creatine level, μmol/L)
2-fold elevation of serum creatine level from baseline
Time frame: 24 months after enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.